ForPatients
by Roche

Neuromyelitis Optica Neuromyelitis optica spectrum disorder (NMOSD)

Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)

Trial Status	Trial Runs In	Trial Identifier
Completed	11 Countries	NCT02028884 2013-003752-21, SA-307JG BN40898

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

The objective of this study is to evaluate the efficacy, safety, pharmacodynamic, pharmacokinetic, and immunogenic profiles of satralizumab, compared with placebo, in addition to baseline immunosuppressive treatment in participants with NMO and NMOSD.

Hoffmann-La Roche	Phase 3
Sponsor	Phase

NCT02028884 2013-003752-21, SA-307JG BN40898
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
All	>=12 Years & <= 74 Years	No

© 2022 F. Hoffmann-La Roche Ltd